Large International Study Pinpoints the Impact of TP53 Mutations On Blood Cancer Severity

A large international study led by researchers at Memorial Sloan Kettering finds that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with worse outcomes in myelodysplastic syndrome and acute myeloid leukemia. The findings have immediate clinical relevance for risk assessment and treatment of people with a blood cancer called myelodysplastic syndrome